SpringerLink
Log in

Epigenetics of Idiopathic Pulmonary Fibrosis

  • Chapter
  • First Online:
Targeting Epigenetics in Inflammatory Lung Diseases

  • 123 Accesses

Abstract

Idiopathic pulmonary fibrosis (IPF) is a fatal variation of the interstitial pulmonary illness characterised by extracellular matrix deposition that leads to secretion of inflammatory cytokines and causes fibrosis in the lungs. Further progression of fibrosis leads to cancerous stage of lungs and death. IPF is the worst pathological condition to be focused on and explored because of its rising prevalence, poor prognosis, and inadequate treatment. Even though the disease’s origin is still unknown, several genetic, environmental, and underlying pulmonary problems could set off a number of molecular pathways which is involved in the development of IPF. However, several genetic loci and genetic polymorphisms linked to IPF have been examined by genome-wide association studies and whole-genome sequencing. The newly found gene may clarify key elements in the identification, prognosis, and treatments of IPF. Additionally IPF can result from a variety of epigenetic alternations, including modification of histone, methylation of DNA, and non-coding RNA. This book chapter summarises the pathogenesis of pulmonary fibrosis, available treatment and the pathways that involved in IPF progression and may develop into lung cancer. Furthermore, this highlights epigenetic and molecular mechanism of IPF progression.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Chapter
EUR 29.95
Price includes VAT (France)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
EUR 128.39
Price includes VAT (France)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
EUR 168.79
Price includes VAT (France)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free ship** worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Martinez FJ, Collard HR, Pardo A, Raghu G, Richeldi L, Selman M, et al. Idiopathic pulmonary fibrosis. Nat Rev Dis Primers. 2017;3:17074. https://doi.org/10.1038/nrdp.2017.74.

    Article  PubMed  Google Scholar 

  2. Richeldi L, Collard HR, Jones MG. Idiopathic pulmonary fibrosis. Lancet. 2017;389(10082):1941–52. https://doi.org/10.1016/s0140-6736(17)30866-8.

    Article  PubMed  Google Scholar 

  3. Lederer DJ, Martinez FJ. Idiopathic pulmonary fibrosis. N Engl J Med. 2018;378(19):1811–23. https://doi.org/10.1056/NEJMra1705751.

    Article  CAS  PubMed  Google Scholar 

  4. Spagnolo P, Kropski JA, Jones MG, Lee JS, Rossi G, Karampitsakos T, et al. Idiopathic pulmonary fibrosis: disease mechanisms and drug development. Pharmacol Ther. 2021;222:107798. https://doi.org/10.1016/j.pharmthera.2020.107798.

    Article  CAS  PubMed  Google Scholar 

  5. Sgalla G, Iovene B, Calvello M, Ori M, Varone F, Richeldi L. Idiopathic pulmonary fibrosis: pathogenesis and management. Respir Res. 2018;19(1):32. https://doi.org/10.1186/s12931-018-0730-2.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Wolters PJ, Collard HR, Jones KD. Pathogenesis of idiopathic pulmonary fibrosis. Annu Rev Pathol. 2014;9:157–79. https://doi.org/10.1146/annurev-pathol-012513-104706.

    Article  CAS  PubMed  Google Scholar 

  7. Maher TM, Bendstrup E, Dron L, Langley J, Smith G, Khalid JM, et al. Global incidence and prevalence of idiopathic pulmonary fibrosis. Respir Res. 2021;22(1):197. https://doi.org/10.1186/s12931-021-01791-z.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Woodcock HV, Maher TM. The treatment of idiopathic pulmonary fibrosis. F1000Prime Rep. 2014;6:16. https://doi.org/10.12703/P6-16.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Mustafin RN. Molecular genetics of idiopathic pulmonary fibrosis. Vavilovskii Zhurnal Genet Selektsii. 2022;26(3):308–18. https://doi.org/10.18699/VJGB-22-37.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Leung J, Cho Y, Lockey RF, Kolliputi N. The role of aging in idiopathic pulmonary fibrosis. Lung. 2015;193(4):605–10. https://doi.org/10.1007/s00408-015-9729-3.

    Article  CAS  PubMed  Google Scholar 

  11. Samarelli AV, Masciale V, Aramini B, Coló GP, Tonelli R, Marchioni A, et al. Molecular mechanisms and cellular contribution from lung fibrosis to lung cancer development. Int J Mol Sci. 2021;22(22) https://doi.org/10.3390/ijms222212179.

  12. Kinoshita T, Goto T. Molecular mechanisms of pulmonary fibrogenesis and its progression to lung cancer: a review. Int J Mol Sci. 2019;20(6) https://doi.org/10.3390/ijms20061461.

  13. Karampitsakos T, Tzilas V, Tringidou R, Steiropoulos P, Aidinis V, Papiris SA, et al. Lung cancer in patients with idiopathic pulmonary fibrosis. Pulm Pharmacol Ther. 2017;45:1–10. https://doi.org/10.1016/j.pupt.2017.03.016.

    Article  CAS  PubMed  Google Scholar 

  14. Ozawa Y, Suda T, Naito T, Enomoto N, Hashimoto D, Fujisawa T, et al. Cumulative incidence of and predictive factors for lung cancer in IPF. Respirology. 2009;14(5):723–8. https://doi.org/10.1111/j.1440-1843.2009.01547.x.

    Article  PubMed  Google Scholar 

  15. Goto T, Maeshima A, Akanabe K, Oyamada Y, Kato R. Acute exacerbation of idiopathic pulmonary fibrosis of microscopic usual interstitial pneumonia pattern after lung cancer surgery<en-aut-mei> </en-aut-mei>. Ann Thorac Cardiovasc Surg. 2011;17(6):573–6. https://doi.org/10.5761/atcs.cr.10.01619.

    Article  PubMed  Google Scholar 

  16. Goto T, Maeshima A, Oyamada Y, Kato R. Idiopathic pulmonary fibrosis as a prognostic factor in non-small cell lung cancer. Int J Clin Oncol. 2014;19(2):266–73. https://doi.org/10.1007/s10147-013-0566-1.

    Article  CAS  PubMed  Google Scholar 

  17. Goto T. Measuring surgery outcomes of lung cancer patients with concomitant pulmonary fibrosis: a review of the literature. Cancers. 2018;10(7):223.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Hendriks LE, Drent M, van Haren EH, Verschakelen JA, Verleden GM. Lung cancer in idiopathic pulmonary fibrosis patients diagnosed during or after lung transplantation. Respir Med Case Rep. 2012;5:37–9. https://doi.org/10.1016/j.rmedc.2011.10.003.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Daniels CE, Jett JR. Does interstitial lung disease predispose to lung cancer? Curr Opin Pulm Med. 2005;11(5):431–7. https://doi.org/10.1097/01.mcp.0000170521.71497.ba.

    Article  PubMed  Google Scholar 

  20. Tomassetti S, Gurioli C, Ryu JH, Decker PA, Ravaglia C, Tantalocco P, et al. The impact of lung cancer on survival of idiopathic pulmonary fibrosis. Chest. 2015;147(1):157–64. https://doi.org/10.1378/chest.14-0359.

    Article  PubMed  Google Scholar 

  21. Antoniou KM, Tomassetti S, Tsitoura E, Vancheri C. Idiopathic pulmonary fibrosis and lung cancer: a clinical and pathogenesis update. Curr Opin Pulm Med. 2015;21(6):626–33. https://doi.org/10.1097/mcp.0000000000000217.

    Article  CAS  PubMed  Google Scholar 

  22. Vancheri C, Failla M, Crimi N, Raghu G. Idiopathic pulmonary fibrosis: a disease with similarities and links to cancer biology. Eur Respir J. 2010;35(3):496–504. https://doi.org/10.1183/09031936.00077309.

    Article  CAS  PubMed  Google Scholar 

  23. Vancheri C. Common pathways in idiopathic pulmonary fibrosis and cancer. Eur Respir Rev. 2013;22(129):265–72. https://doi.org/10.1183/09059180.00003613.

    Article  PubMed  PubMed Central  Google Scholar 

  24. El Agha E, Moiseenko A, Kheirollahi V, De Langhe S, Crnkovic S, Kwapiszewska G, et al. Two-way conversion between lipogenic and myogenic fibroblastic phenotypes marks the progression and resolution of lung fibrosis. Cell Stem Cell. 2017;20(2):261–73.e3. https://doi.org/10.1016/j.stem.2016.10.004.

    Article  CAS  PubMed  Google Scholar 

  25. Luo YH, Wang C, Xu WT, Zhang Y, Zhang T, Xue H, et al. 18β-glycyrrhetinic acid has anti-cancer effects via inducing apoptosis and G2/M cell cycle arrest, and inhibiting migration of A549 lung cancer cells. Onco Targets Ther. 2021;14:5131–44. https://doi.org/10.2147/ott.S322852.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Pallante P, Malapelle U, Nacchio M, Sgariglia R, Galati D, Capitelli L, et al. Liquid biopsy is a promising tool for genetic testing in idiopathic pulmonary fibrosis. Diagnostics. 2021;11(7):1202.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Jovanovic D, Roksandic Milenkovic M, Kotur Stevuljevic J, Markovic J, Ceriman V, Kontic M, et al. Membrane PD-L1 expression and soluble PD-L1 plasma levels in idiopathic pulmonary fibrosis-a pilot study. J Thorac Dis. 2018;10(12):6660–9. https://doi.org/10.21037/jtd.2018.11.16.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Marriott S, Baskir RS, Gaskill C, Menon S, Carrier EJ, Williams J, et al. ABCG2pos lung mesenchymal stem cells are a novel pericyte subpopulation that contributes to fibrotic remodeling. Am J Physiol Cell Physiol. 2014;307(8):C684–98. https://doi.org/10.1152/ajpcell.00114.2014.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Karki S, Surolia R, Hock TD, Guroji P, Zolak JS, Duggal R, et al. Wilms’ tumor 1 (Wt1) regulates pleural mesothelial cell plasticity and transition into myofibroblasts in idiopathic pulmonary fibrosis. FASEB J. 2014;28(3):1122–31. https://doi.org/10.1096/fj.13-236828.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Rock JR, Barkauskas CE, Cronce MJ, Xue Y, Harris JR, Liang J, et al. Multiple stromal populations contribute to pulmonary fibrosis without evidence for epithelial to mesenchymal transition. Proc Natl Acad Sci U S A. 2011;108(52):E1475–83. https://doi.org/10.1073/pnas.1117988108.

    Article  PubMed  PubMed Central  Google Scholar 

  31. Strieter RM, Keeley EC, Hughes MA, Burdick MD, Mehrad B. The role of circulating mesenchymal progenitor cells (fibrocytes) in the pathogenesis of pulmonary fibrosis. J Leuk Biol. 2009;86(5):1111–8. https://doi.org/10.1189/jlb.0309132.

    Article  CAS  Google Scholar 

  32. Shiga K, Hara M, Nagasaki T, Sato T, Takahashi H, Takeyama H. Cancer-associated fibroblasts: their characteristics and their roles in tumor growth. Cancers (Basel). 2015;7(4):2443–58. https://doi.org/10.3390/cancers7040902.

    Article  PubMed  Google Scholar 

  33. Chen Q, Chen S, Zhao J, Zhou Y, Xu L. MicroRNA-126: a new and promising player in lung cancer. Oncol Lett. 2021;21(1):35. https://doi.org/10.3892/ol.2020.12296.

    Article  CAS  PubMed  Google Scholar 

  34. Domen A, Quatannens D, Zanivan S, Deben C, Van Audenaerde J, Smits E, et al. Cancer-associated fibroblasts as a common orchestrator of therapy resistance in lung and pancreatic cancer. Cancers (Basel). 2021;13(5) https://doi.org/10.3390/cancers13050987.

  35. Bochet L, Lehuédé C, Dauvillier S, Wang YY, Dirat B, Laurent V, et al. Adipocyte-derived fibroblasts promote tumor progression and contribute to the desmoplastic reaction in breast cancer. Cancer Res. 2013;73(18):5657–68. https://doi.org/10.1158/0008-5472.Can-13-0530.

    Article  CAS  PubMed  Google Scholar 

  36. De P, Aske J, Dey N. Cancer-associated fibroblast functions as a road-block in cancer therapy. Cancers (Basel). 2021;13(20) https://doi.org/10.3390/cancers13205246.

  37. Monteran L, Erez N. The dark side of fibroblasts: cancer-associated fibroblasts as mediators of immunosuppression in the tumor microenvironment. Front Immunol. 2019;1835

    Google Scholar 

  38. De Jaeghere EA, Denys HG, De Wever O. Fibroblasts fuel immune escape in the tumor microenvironment. Trends Cancer. 2019;5(11):704–23. https://doi.org/10.1016/j.trecan.2019.09.009.

    Article  CAS  PubMed  Google Scholar 

  39. Yazdani S, Bansal R, Prakash J. Drug targeting to myofibroblasts: implications for fibrosis and cancer. Adv Drug Deliv Rev. 2017;121:101–16. https://doi.org/10.1016/j.addr.2017.07.010.

    Article  CAS  PubMed  Google Scholar 

  40. Caja L, Dituri F, Mancarella S, Caballero-Diaz D, Moustakas A, Giannelli G, et al. TGF-β and the tissue microenvironment: relevance in fibrosis and cancer. Int J Mol Sci. 2018;19(5):1294.

    Article  PubMed  PubMed Central  Google Scholar 

  41. Chen P-Y, Wei W-F, Wu H-Z, Fan L-S, Wang W. Cancer-associated fibroblast heterogeneity: a factor that cannot be ignored in immune microenvironment remodeling. Front Immunol. 2021;12:2760.

    Google Scholar 

  42. Ji X, Ji J, Shan F, Zhang Y, Chen Y, Lu X. Cancer-associated fibroblasts from NSCLC promote the radioresistance in lung cancer cell lines. Int J Clin Exp Med. 2015;8(5):7002–8.

    PubMed  PubMed Central  Google Scholar 

  43. Hua W, ten Dijke P, Kostidis S, Giera M, Hornsveld M. TGFβ-induced metabolic reprogramming during epithelial-to-mesenchymal transition in cancer. Cell Mol Life Sci. 2020;77(11):2103–23. https://doi.org/10.1007/s00018-019-03398-6.

    Article  CAS  PubMed  Google Scholar 

  44. Pereira BA, Vennin C, Papanicolaou M, Chambers CR, Herrmann D, Morton JP, et al. CAF subpopulations: a new reservoir of stromal targets in pancreatic cancer. Trends Cancer. 2019;5(11):724–41. https://doi.org/10.1016/j.trecan.2019.09.010.

    Article  PubMed  Google Scholar 

  45. Losa D, Chanson M, Crespin S. Connexins as therapeutic targets in lung disease. Expert Opin Ther Targets. 2011;15(8):989–1002. https://doi.org/10.1517/14728222.2011.584875.

    Article  CAS  PubMed  Google Scholar 

  46. Mori R, Power KT, Wang CM, Martin P, Becker DL. Acute downregulation of connexin43 at wound sites leads to a reduced inflammatory response, enhanced keratinocyte proliferation and wound fibroblast migration. J Cell Sci. 2006;119(24):5193–203. https://doi.org/10.1242/jcs.03320.

    Article  CAS  PubMed  Google Scholar 

  47. Cesen-Cummings K, Fernstrom MJ, Malkinson AM, Ruch RJ. Frequent reduction of gap junctional intercellular communication and connexin43 expression in human and mouse lung carcinoma cells. Carcinogenesis. 1998;19(1):61–7. https://doi.org/10.1093/carcin/19.1.61.

    Article  CAS  PubMed  Google Scholar 

  48. Trovato-Salinaro A, Trovato-Salinaro E, Failla M, Mastruzzo C, Tomaselli V, Gili E, et al. Altered intercellular communication in lung fibroblast cultures from patients with idiopathic pulmonary fibrosis. Respir Res. 2006;7(1):122. https://doi.org/10.1186/1465-9921-7-122.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Mazieres J, He B, You L, Xu Z, Jablons DM. Wnt signaling in lung cancer. Cancer Lett. 2005;222(1):1–10. https://doi.org/10.1016/j.canlet.2004.08.040.

    Article  CAS  PubMed  Google Scholar 

  50. Hoguin A, Rastogi A, Bowler C, Tirichine L. Genome-wide analysis of allele-specific expression of genes in the model diatom Phaeodactylum tricornutum. Sci Rep. 2021;11(1):2954. https://doi.org/10.1038/s41598-021-82529-1.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Caraci F, Gili E, Calafiore M, Failla M, La Rosa C, Crimi N, et al. TGF-beta1 targets the GSK-3beta/beta-catenin pathway via ERK activation in the transition of human lung fibroblasts into myofibroblasts. Pharmacol Res. 2008;57(4):274–82. https://doi.org/10.1016/j.phrs.2008.02.001.

    Article  CAS  PubMed  Google Scholar 

  52. Conte E, Fruciano M, Fagone E, Gili E, Caraci F, Iemmolo M, et al. Inhibition of PI3K prevents the proliferation and differentiation of human lung fibroblasts into myofibroblasts: the role of class I P110 isoforms. PLoS One. 2011;6(10):e24663.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Guerreiro AS, Fattet S, Kulesza DW, Atamer A, Elsing AN, Shalaby T, et al. A Sensitized RNA interference screen identifies a novel role for the PI3K p110γ isoform in medulloblastoma cell proliferation and chemoresistance. Mol Cancer Res. 2011;9(7):925–35. https://doi.org/10.1158/1541-7786.Mcr-10-0200.

    Article  CAS  PubMed  Google Scholar 

  54. Grimminger F, Schermuly RT, Ghofrani HA. Targeting non-malignant disorders with tyrosine kinase inhibitors. Nat Rev Drug Discov. 2010;9(12):956–70. https://doi.org/10.1038/nrd3297.

    Article  CAS  PubMed  Google Scholar 

  55. Malli F, Koutsokera A, Paraskeva E, Zakynthinos E, Papagianni M, Makris D, et al. Endothelial progenitor cells in the pathogenesis of idiopathic pulmonary fibrosis: an evolving concept. PLoS One. 2013;8(1):e53658. https://doi.org/10.1371/journal.pone.0053658.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  56. Sakai T, Satoh K, Matsushima K, Shindo S, Abe S, Abe T, et al. Hepatocyte growth factor in bronchoalveolar lavage fluids and cells in patients with inflammatory chest diseases of the lower respiratory tract: detection by RIA and in situ hybridization. Am J Respir Cell Mol Biol. 1997;16(4):388–97. https://doi.org/10.1165/ajrcmb.16.4.9115749.

    Article  CAS  PubMed  Google Scholar 

  57. Maeda J, Ueki N, Hada T, Higashino K. Elevated serum hepatocyte growth factor/scatter factor levels in inflammatory lung disease. Am J Respir Crit Care Med. 1995;152(5):1587–91. https://doi.org/10.1164/ajrccm.152.5.7582299.

    Article  CAS  PubMed  Google Scholar 

  58. Shiratori M, Michalopoulos G, Shinozuka H, Singh G, Ogasawara H, Katyal SL. Hepatocyte growth factor stimulates DNA synthesis in alveolar epithelial type II cells in vitro. Am J Respir Cell Mol Biol. 1995;12(2):171–80. https://doi.org/10.1165/ajrcmb.12.2.7532419.

    Article  CAS  PubMed  Google Scholar 

  59. Yaekashiwa M, Nakayama S, Ohnuma K, Sakai T, Abe T, Satoh K, et al. Simultaneous or delayed administration of hepatocyte growth factor equally represses the fibrotic changes in murine lung injury induced by bleomycin. Am J Respir Crit Care Med. 1997;156(6):1937–44. https://doi.org/10.1164/ajrccm.156.6.9611057.

    Article  CAS  PubMed  Google Scholar 

  60. Panganiban RA, Day RM. Hepatocyte growth factor in lung repair and pulmonary fibrosis. Acta Pharmacol Sin. 2011;32(1):12–20. https://doi.org/10.1038/aps.2010.90.

    Article  CAS  PubMed  Google Scholar 

  61. Noth I, Zhang Y, Ma SF, Flores C, Barber M, Huang Y, et al. Genetic variants associated with idiopathic pulmonary fibrosis susceptibility and mortality: a genome-wide association study. Lancet Respir Med. 2013;1(4):309–17. https://doi.org/10.1016/s2213-2600(13)70045-6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  62. Nathan N, Giraud V, Picard C, Nunes H, Dastot-Le Moal F, Copin B, et al. Germline SFTPA1 mutation in familial idiopathic interstitial pneumonia and lung cancer. Hum Mol Genet. 2016;25(8):1457–67. https://doi.org/10.1093/hmg/ddw014.

    Article  CAS  PubMed  Google Scholar 

  63. Wang Y, Kuan PJ, **ng C, Cronkhite JT, Torres F, Rosenblatt RL, et al. Genetic defects in surfactant protein A2 are associated with pulmonary fibrosis and lung cancer. Am J Hum Genet. 2009;84(1):52–9. https://doi.org/10.1016/j.ajhg.2008.11.010.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  64. Crossno PF, Polosukhin VV, Blackwell TS, Johnson JE, Markin C, Moore PE, et al. Identification of early interstitial lung disease in an individual with genetic variations in ABCA3 and SFTPC. Chest. 2010;137(4):969–73. https://doi.org/10.1378/chest.09-0790.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  65. Stanley SE, Gable DL, Wagner CL, Carlile TM, Hanumanthu VS, Podlevsky JD, et al. Loss-of-function mutations in the RNA biogenesis factor NAF1 predispose to pulmonary fibrosis-emphysema. Sci Transl Med. 2016;8(351):351ra107. https://doi.org/10.1126/scitranslmed.aaf7837.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  66. Kaur A, Mathai SK, Schwartz DA. Genetics in idiopathic pulmonary fibrosis pathogenesis, prognosis, and treatment. Front Med. 2017;4 https://doi.org/10.3389/fmed.2017.00154.

  67. Nogee LM, Dunbar AE 3rd, Wert SE, Askin F, Hamvas A, Whitsett JA. A mutation in the surfactant protein C gene associated with familial interstitial lung disease. N Engl J Med. 2001;344(8):573–9. https://doi.org/10.1056/nejm200102223440805.

    Article  CAS  PubMed  Google Scholar 

  68. Thomas AQ, Lane KF, Phillips JA, Prince MA, Markin CR, Speer MC, et al. Heterozygosity for a surfactant protein C gene mutation associated with usual interstitial pneumonitis and cellular nonspecific interstitial pneumonitis in one kindred. Am J Respir Crit Care Med. 2002;165(9):1322–8.

    Article  PubMed  Google Scholar 

  69. Brasch F, Griese M, Tredano M, Johnen G, Ochs M, Rieger C, et al. Interstitial lung disease in a baby with a de novo mutation in the SFTPC gene. Eur Respir J. 2004;24(1):30–9. https://doi.org/10.1183/09031936.04.00000104.

    Article  CAS  PubMed  Google Scholar 

  70. Li J, Liepinsh E, Almlén A, Thyberg J, Curstedt T, Jörnvall H, et al. Structure and influence on stability and activity of the N-terminal propeptide part of lung surfactant protein C. FEBS J. 2006;273(5):926–35. https://doi.org/10.1111/j.1742-4658.2006.05124.x.

    Article  CAS  PubMed  Google Scholar 

  71. Maguire JA, Mulugeta S, Beers MF. Multiple ways to die: delineation of the unfolded protein response and apoptosis induced by Surfactant Protein C BRICHOS mutants. Int J Biochem Cell Biol. 2012;44(1):101–12. https://doi.org/10.1016/j.biocel.2011.10.003.

    Article  CAS  PubMed  Google Scholar 

  72. Lawson WE, Cheng D-S, Degryse AL, Tanjore H, Polosukhin VV, Xu XC, et al. Endoplasmic reticulum stress enhances fibrotic remodeling in the lungs. Proc Natl Acad Sci U S A. 2011;108(26):10562–7. https://doi.org/10.1073/pnas.1107559108.

    Article  PubMed  PubMed Central  Google Scholar 

  73. Willander H, Hermansson E, Johansson J, Presto J. BRICHOS domain associated with lung fibrosis, dementia and cancer--a chaperone that prevents amyloid fibril formation? FEBS J. 2011;278(20):3893–904. https://doi.org/10.1111/j.1742-4658.2011.08209.x.

    Article  CAS  PubMed  Google Scholar 

  74. Tanjore H, Cheng DS, Degryse AL, Zoz DF, Abdolrasulnia R, Lawson WE, et al. Alveolar epithelial cells undergo epithelial-to-mesenchymal transition in response to endoplasmic reticulum stress. J Biol Chem. 2015;290(6):3277. https://doi.org/10.1074/jbc.A110.181164.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  75. Zhou W, Wang Y. Candidate genes of idiopathic pulmonary fibrosis: current evidence and research. Appl Clin Genet. 2016;9:5–13. https://doi.org/10.2147/tacg.S61999.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  76. Armanios M. Telomerase and idiopathic pulmonary fibrosis. Mutat Res. 2012;730(1–2):52–8. https://doi.org/10.1016/j.mrfmmm.2011.10.013.

    Article  CAS  PubMed  Google Scholar 

  77. Seibold MA, Wise AL, Speer MC, Steele MP, Brown KK, Loyd JE, et al. A common MUC5B promoter polymorphism and pulmonary fibrosis. N Engl J Med. 2011;364(16):1503–12. https://doi.org/10.1056/NEJMoa1013660.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  78. Fingerlin TE, Murphy E, Zhang W, Peljto AL, Brown KK, Steele MP, et al. Genome-wide association study identifies multiple susceptibility loci for pulmonary fibrosis. Nat Genet. 2013;45(6):613–20. https://doi.org/10.1038/ng.2609.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  79. Peljto AL, Selman M, Kim DS, Murphy E, Tucker L, Pardo A, et al. The MUC5B promoter polymorphism is associated with idiopathic pulmonary fibrosis in a Mexican cohort but is rare among Asian ancestries. Chest. 2015;147(2):460–4.

    Article  PubMed  Google Scholar 

  80. Wei R, Li C, Zhang M, Jones-Hall YL, Myers JL, Noth I, et al. Association between MUC5B and TERT polymorphisms and different interstitial lung disease phenotypes. Transl Res. 2014;163(5):494–502.

    Article  CAS  PubMed  Google Scholar 

  81. Seibold MA, Smith RW, Urbanek C, Groshong SD, Cosgrove GP, Brown KK, et al. The idiopathic pulmonary fibrosis honeycomb cyst contains a mucocilary pseudostratified epithelium. PLoS One. 2013;8(3):e58658. https://doi.org/10.1371/journal.pone.0058658.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  82. Roy MG, Livraghi-Butrico A, Fletcher AA, McElwee MM, Evans SE, Boerner RM, et al. Muc5b is required for airway defence. Nature. 2014;505(7483):412–6. https://doi.org/10.1038/nature12807.

    Article  CAS  PubMed  Google Scholar 

  83. Yang IV, Fingerlin TE, Evans CM, Schwarz MI, Schwartz DA. MUC5B and idiopathic pulmonary fibrosis. Ann Am Thoracic Soc. 2015;12 Suppl 2(Suppl 2):S193–9. https://doi.org/10.1513/AnnalsATS.201503-110AW.

    Article  Google Scholar 

  84. Karampitsakos T, Woolard T, Bouros D, Tzouvelekis A. Toll-like receptors in the pathogenesis of pulmonary fibrosis. Eur J Pharmacol. 2017;808:35–43. https://doi.org/10.1016/j.ejphar.2016.06.045.

    Article  CAS  PubMed  Google Scholar 

  85. Kawasaki T, Kawai T. Toll-like receptor signaling pathways. Front Immunol. 2014;5 https://doi.org/10.3389/fimmu.2014.00461.

  86. Zhang G, Ghosh S. Negative regulation of toll-like receptor-mediated signaling by tollip*. J Biol Chem. 2002;277(9):7059–65. https://doi.org/10.1074/jbc.M109537200.

    Article  CAS  PubMed  Google Scholar 

  87. Didierlaurent A, Brissoni B, Velin D, Aebi N, Tardivel A, Käslin E, et al. Tollip regulates proinflammatory responses to interleukin-1 and lipopolysaccharide. Mol Cell Biol. 2006;26(3):735–42. https://doi.org/10.1128/MCB.26.3.735-742.2006.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  88. Kowalski EJA, Li L. Toll-interacting protein in resolving and non-resolving inflammation. (1664–3224 (Print)).

    Google Scholar 

  89. van der Mark VA, Ghiboub M, Marsman C, Zhao J, van Dijk R, Hiralall JK, et al. Phospholipid flippases attenuate LPS-induced TLR4 signaling by mediating endocytic retrieval of Toll-like receptor 4. Cell Mol Life Sci. 2017;74(4):715–30. https://doi.org/10.1007/s00018-016-2360-5.

    Article  CAS  PubMed  Google Scholar 

  90. Trujillo G, Meneghin A, Flaherty KR, Sholl LM, Myers JL, Kazerooni EA, et al. TLR9 differentiates rapidly from slowly progressing forms of idiopathic pulmonary fibrosis. Sci Transl Med. 2010;2(57):57ra82. https://doi.org/10.1126/scitranslmed.3001510.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  91. Korthagen NM, van Moorsel CHM, Kazemier KM, Ruven HJT, Grutters JC. IL1RN genetic variations and risk of IPF: a meta-analysis and mRNA expression study. Immunogenetics. 2012;64(5):371–7. https://doi.org/10.1007/s00251-012-0604-6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  92. Gasse P, Mary C, Guenon I, Noulin N, Charron S, Schnyder-Candrian S, et al. IL-1R1/MyD88 signaling and the inflammasome are essential in pulmonary inflammation and fibrosis in mice. J Clin Invest. 2007;117(12):3786–99. https://doi.org/10.1172/jci32285.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  93. Borthwick LA. The IL-1 cytokine family and its role in inflammation and fibrosis in the lung. Semin Immunopathol. 2016;38(4):517–34. https://doi.org/10.1007/s00281-016-0559-z.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  94. Michalski JE, Schwartz DA. Genetic risk factors for idiopathic pulmonary fibrosis: insights into immunopathogenesis. J Inflamm Res. 2020;13:1305–18. https://doi.org/10.2147/jir.S280958.

    Article  CAS  PubMed  Google Scholar 

  95. Bruder E, Hofmeister J, Aslanidis C, Hammer J, Bubendorf L, Schmitz G, et al. Ultrastructural and molecular analysis in fatal neonatal interstitial pneumonia caused by a novel ABCA3 mutation. Mod Pathol. 2007;20(10):1009–18. https://doi.org/10.1038/modpathol.3800928.

    Article  CAS  PubMed  Google Scholar 

  96. Campo I, Zorzetto M, Mariani F, Kadija Z, Morbini P, Dore R, et al. A large kindred of pulmonary fibrosis associated with a novel ABCA3 gene variant. Respir Res. 2014;15(1):43. https://doi.org/10.1186/1465-9921-15-43.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  97. Ciantelli M, Ghirri P, Presi S, Sigali E, Vuerich M, Somaschini M, et al. Fatal respiratory failure in a full-term newborn with two ABCA3 gene mutations: a case report. J Perinatol. 2011;31(1):70–2. https://doi.org/10.1038/jp.2010.122.

    Article  CAS  PubMed  Google Scholar 

  98. Pandit KV, Milosevic J, Kaminski N. MicroRNAs in idiopathic pulmonary fibrosis. Transl Res. 2011;157(4):191–9. https://doi.org/10.1016/j.trsl.2011.01.012.

    Article  CAS  PubMed  Google Scholar 

  99. Sanders YY, Kumbla P, Hagood JS. Enhanced myofibroblastic differentiation and survival in Thy-1 (−) lung fibroblasts. Am J Respir Cell Mol Biol. 2007;36(2):226–35.

    Article  CAS  PubMed  Google Scholar 

  100. Sanders YY, Pardo A, Selman M, Nuovo GJ, Tollefsbol TO, Siegal GP, et al. Thy-1 promoter hypermethylation: a novel epigenetic pathogenic mechanism in pulmonary fibrosis. Am J Respir Cell Mol Biol. 2008;39(5):610–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  101. Kuwano K, Kunitake R, Kawasaki M, Nomoto Y, Hagimoto N, Nakanishi Y, et al. P21Waf1/Cip1/Sdi1 and p53 expression in association with DNA strand breaks in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 1996;154(2 Pt 1):477–83. https://doi.org/10.1164/ajrccm.154.2.8756825.

    Article  CAS  PubMed  Google Scholar 

  102. Hojo S, Fujita J, Yamadori I, Kamei T, Yoshinouchi T, Ohtsuki Y, et al. Heterogeneous point mutations of the p53 gene in pulmonary fibrosis. Eur Respir J. 1998;12(6):1404–8. https://doi.org/10.1183/09031936.98.12061404.

    Article  CAS  PubMed  Google Scholar 

  103. Uematsu K, Yoshimura A, Gemma A, Mochimaru H, Hosoya Y, Kunugi S, et al. Aberrations in the fragile histidine triad (FHIT) gene in idiopathic pulmonary fibrosis. Cancer Res. 2001;61(23):8527–33.

    CAS  PubMed  Google Scholar 

  104. Demopoulos K, Arvanitis DA, Vassilakis DA, Siafakas NM, Spandidos DA. MYCL1, FHIT, SPARC, p16(INK4) and TP53 genes associated to lung cancer in idiopathic pulmonary fibrosis. J Cell Mol Med. 2002;6(2):215–22. https://doi.org/10.1111/j.1582-4934.2002.tb00188.x.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  105. Rosales W, Carulla J, García J, Vargas D, Lizcano F. Role of histone demethylases in cardiomyocytes induced to hypertrophy. Biomed Res Int. 2016;2016:2634976. https://doi.org/10.1155/2016/2634976.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  106. Correll KA, Edeen KE, Redente EF, Zemans RL, Edelman BL, Danhorn T, et al. TGF beta inhibits HGF, FGF7, and FGF10 expression in normal and IPF lung fibroblasts. Physiol Rep. 2018;6(16):e13794. https://doi.org/10.14814/phy2.13794.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  107. Lovat F, Valeri N, Croce CM. MicroRNAs in the pathogenesis of Cancer. Semin Oncol. 2011;38(6):724–33. https://doi.org/10.1053/j.seminoncol.2011.08.006.

    Article  CAS  PubMed  Google Scholar 

  108. Oak SR, Murray L, Herath A, Sleeman M, Anderson I, Joshi AD, et al. A micro RNA processing defect in rapidly progressing idiopathic pulmonary fibrosis. PLoS One. 2011;6(6):e21253. https://doi.org/10.1371/journal.pone.0021253.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  109. Corella D, Ordovas JM. Basic concepts in molecular biology related to genetics and epigenetics. Rev Española Cardiol (English Edition). 2017;70(9):744–53. https://doi.org/10.1016/j.rec.2017.05.011.

    Article  Google Scholar 

  110. Roach KM, Feghali-Bostwick CA, Amrani Y, Bradding P. Lipoxin A4 attenuates constitutive and TGF-β1–dependent profibrotic activity in human lung myofibroblasts. J Immunol. 2015;195(6):2852–60.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  111. Samara KD, Trachalaki A, Tsitoura E, Koutsopoulos AV, Lagoudaki ED, Lasithiotaki I, et al. Upregulation of citrullination pathway: from autoimmune to idiopathic lung fibrosis. Respir Res. 2017;18(1):218. https://doi.org/10.1186/s12931-017-0692-9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  112. Yang IV, Schwartz DA. Epigenetics of idiopathic pulmonary fibrosis. Transl Res. 2015;165(1):48–60. https://doi.org/10.1016/j.trsl.2014.03.011.

    Article  CAS  PubMed  Google Scholar 

  113. Yang IV. Epigenomics of idiopathic pulmonary fibrosis. (1750-192X (Electronic)).

    Google Scholar 

  114. Yang IV, Schwartz DA. Epigenetic control of gene expression in the lung. Am J Respir Crit Care Med. 2011;183(10):1295–301. https://doi.org/10.1164/rccm.201010-1579PP.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  115. Penz-Österreicher M, Österreicher CH, Trauner M. Fibrosis in autoimmune and cholestatic liver disease. Best Pract Res Clin Gastroenterol. 2011;25(2):245–58. https://doi.org/10.1016/j.bpg.2011.02.001.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  116. Ding Q, Luckhardt T, Hecker L, Zhou Y, Liu G, Antony VB, deAndrade J, et al. New insights into the pathogenesis and treatment of idiopathic pulmonary fibrosis. (1179–1950 (Electronic)).

    Google Scholar 

  117. Zong D, Liu X, Li J, Ouyang R, Chen P. The role of cigarette smoke-induced epigenetic alterations in inflammation. Epigenetics Chromatin. 2019;12(1):65. https://doi.org/10.1186/s13072-019-0311-8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  118. Pardo A, Selman M. The interplay of the genetic architecture, aging, and environmental factors in the pathogenesis of idiopathic pulmonary fibrosis. Am J Respir Cell Mol Biol. 2021;64(2):163–72. https://doi.org/10.1165/rcmb.2020-0373PS.

    Article  CAS  PubMed  Google Scholar 

  119. Sanders YY, Pardo A, Selman M, Nuovo GJ, Tollefsbol TO, Siegal GP, et al. Thy-1 promoter hypermethylation: a novel epigenetic pathogenic mechanism in pulmonary fibrosis. Am J Respir Cell Mol Biol. 2008;39(5):610–8. https://doi.org/10.1165/rcmb.2007-0322OC.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  120. Hu B, Gharaee-Kermani M, Wu Z, Phan SH. Epigenetic regulation of myofibroblast differentiation by DNA methylation. (1525–2191 (Electronic)).

    Google Scholar 

  121. Tzouvelekis A, Kaminski N. Epigenetics in idiopathic pulmonary fibrosis. Biochem Cell Biol. 2015;93(2):159–70. https://doi.org/10.1139/bcb-2014-0126.

    Article  CAS  PubMed  Google Scholar 

  122. Seto E, Yoshida M. Erasers of histone acetylation: the histone deacetylase enzymes. (1943–0264 (Electronic)).

    Google Scholar 

  123. Sehgal M, Jakhete SM, Manekar AG, Sasikumar S. Specific epigenetic regulators serve as potential therapeutic targets in idiopathic pulmonary fibrosis. Heliyon. 2022;8(8):e09773. https://doi.org/10.1016/j.heliyon.2022.e09773.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  124. Zhang M, Serna-Salas S, Damba T, Borghesan M, Demaria M, Moshage H. Hepatic stellate cell senescence in liver fibrosis: characteristics, mechanisms and perspectives. Mech Ageing Dev. 2021;199:111572. https://doi.org/10.1016/j.mad.2021.111572.

    Article  CAS  PubMed  Google Scholar 

  125. Sanders YY, Liu H, Scruggs AM, Duncan SR, Huang SK, Thannickal VJ. Epigenetic regulation of caveolin-1 gene expression in lung fibroblasts. Am J Respir Cell Mol Biol. 2017;56(1):50–61. https://doi.org/10.1165/rcmb.2016-0034OC.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  126. Dakhlallah D, Batte K, Wang Y, Cantemir-Stone CZ, Yan P, Nuovo G, et al. Epigenetic regulation of miR-17~92 contributes to the pathogenesis of pulmonary fibrosis. Am J Respir Crit Care Med. 2013;187(4):397–405. https://doi.org/10.1164/rccm.201205-0888OC.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  127. Lamas DJ, Kawut Smu, Bagiella E, Philip N, Arcasoy SM, Lederer DJ. Delayed access and survival in idiopathic pulmonary fibrosis: a cohort study. (1535–4970 (Electronic)).

    Google Scholar 

  128. Abuserewa ST, Duff R, Becker G. Treatment of idiopathic pulmonary fibrosis. Cureus. 2021;13(5):e15360. https://doi.org/10.7759/cureus.15360.

    Article  PubMed  PubMed Central  Google Scholar 

  129. Noth I, Anstrom KJ, Calvert SB, de Andrade J, Flaherty KR, Glazer C, Kaner RJ, et al. A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis. (1535–4970 (Electronic)).

    Google Scholar 

  130. Malouf MA, Hopkins P, Snell G, Glanville AR. An investigator-driven study of everolimus in surgical lung biopsy confirmed idiopathic pulmonary fibrosis. (1440–1843 (Electronic)).

    Google Scholar 

  131. King TE, Jr., Behr J, Brown KK, du Bois RM, Lancaster L, de Andrade JA, Stähler G, et al. BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. (1535–4970 (Electronic)).

    Google Scholar 

  132. Raghu G, Behr J, Brown KK, Egan JJ, Kawut SM, Flaherty KR, Martinez FJ, et al. Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trial. (1539–3704 (Electronic)).

    Google Scholar 

  133. Raghu G, Million-Rousseau R, Morganti A, Perchenet L, Behr J. Macitentan for the treatment of idiopathic pulmonary fibrosis: the randomised controlled MUSIC trial. (1399–3003 (Electronic)).

    Google Scholar 

  134. Zisman Da, Schwarz M, Anstrom KJ, Collard HR, Flaherty KR, Hunninghake GW. A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis. (1533–4406 (Electronic)).

    Google Scholar 

  135. Raghu G, Brown Kk, Costabel U, Cottin V, du Bois RM, Lasky JA, Thomeer M, et al. Treatment of idiopathic pulmonary fibrosis with etanercept: an exploratory, placebo-controlled trial. (1535–4970 (Electronic)).

    Google Scholar 

  136. Daniels CE, Lasky Ja, Limper AH, Mieras K, Gabor E, Schroeder DR. Imatinib treatment for idiopathic pulmonary fibrosis: Randomized placebo-controlled trial results. (1535–4970 (Electronic)).

    Google Scholar 

  137. Helling BA, Yang IV. Epigenetics in lung fibrosis: from pathobiology to treatment perspective. Curr Opin Pulm Med. 2015;21(5):454–62. https://doi.org/10.1097/MCP.0000000000000191.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

Author would like to acknowledge infrastructure facility and Research Seed Money provided by the Central University of Punjab, Bathinda, and UGC Start-Up grant from UGC-BSR and PECFAR fellowship by IGSTC. PY would like to acknowledge the SRF fellowship received from ICMR.

Conflict of Interest

None.

Author information

Author notes

  1. Sumeet Kumar Singh, Sampat Singh Tanwar, Dhaneshvaree Patel, and Poonam Yadav are contributed equally to this work.

Authors and Affiliations

  1. Department of Pharmacology, Central University of Punjab, Bathinda, India

    Sumeet Kumar Singh, Sampat Singh Tanwar, Dhaneshvaree Patel, Poonam Yadav, Sonu Rajput, Anjali Sharma & Umashanker Navik

  2. Department of Human Genetics and Molecular Medicine, Central University of Punjab, Bathinda, India

    Jasvinder Singh Bhatti

  3. Institute of Molecular Pathobiochemistry, Experimental Gene Therapy and Clinical Chemistry (IFMPEGKC), RWTH Aachen University Hospital, Aachen, Germany

    Amit Khurana

Authors
  1. Sumeet Kumar Singh
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sampat Singh Tanwar
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Dhaneshvaree Patel
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Poonam Yadav
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Sonu Rajput
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Anjali Sharma
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Jasvinder Singh Bhatti
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Amit Khurana
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Umashanker Navik
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. School of Pharmacy, Suresh Gyan University, Jaipur, Rajasthan, India

    Gaurav Gupta

  2. Department of Science, University of Technology Sydney, Ultimo, NSW, Australia

    Brian G. Oliver

  3. Discipline of Pharmacy, University of Technology Sydney, Schofields, NSW, Australia

    Kamal Dua

  4. Division of Pulmonary and Critical Care Medicine, Stanford Medicine, Stanford, CA, USA

    Md Khadem Ali

  5. School of Pharmacy, Gyan Vihar University, Jaipur, Rajasthan, India

    Piyush Dave

Rights and permissions

Reprints and permissions

Copyright information

© 2023 The Author(s), under exclusive license to Springer Nature Singapore Pte Ltd.

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Singh, S.K. et al. (2023). Epigenetics of Idiopathic Pulmonary Fibrosis. In: Gupta, G., Oliver, B.G., Dua, K., Ali, M.K., Dave, P. (eds) Targeting Epigenetics in Inflammatory Lung Diseases. Springer, Singapore. https://doi.org/10.1007/978-981-99-4780-5_9

Download citation

Publish with us

Policies and ethics

Search

Navigation